My approach focuses on meeting cash flow needs with portfolio cash flows (dividends and interest) with a focus on high and rising dividend yields. I take interest in the entire capital structure of a company to (try to) capitalize on inefficiencies between stock and bond markets.
What may make a horrible stock investment may also be an incredible bond investment (and vice versa)!
On top of earning the right to use the Chartered Financial Analyst designation (CFA) I also sport an Undergraduate Finance degree and an MBA concentrating in Analytical Finance, both from top tier schools.
I have a diverse background—as a financial journalist, resident physician, mixed martial artist, painter, entrepreneur, chemistry instructor and web developer—that enabled me to pioneer the “Integrated Investing Research” approach.
I provide consulting to clients, both the retail and professional investors. I accurately forecasted many clinical trials, such as the Flint Trials for Intercept, the Ascend Trials for InterMune and the Affinity Trials MannKind, just to name a few. Through Vincata Enterprises, LLC, I helped many clients to unlock substantial values for their investments.
As an expert in biopharmaceutical analysis, I am also more than capable of analyzing any other industries. Though not shown on Seeking Alpha, I have picked an aggregate basket of outperforming stocks.
Investing in biotech is highly risky, but it can be quite rewarding when investors have an edge in data analysis. Physicians who are rigidly scientific tend to lack the analytical prowess of financial experts. Conversely, financiers usually do not possess a physician’s medical expertise. Likewise, scientists are skillful in data analysis; yet they might not be familiar with a physician’s prescribing patterns, which is a requisite to successful biotech investing.
You can visit my website at https://www.retailinvestor360.com for business inquiry.
I am Seeking Alpha's CEO and Editor-in-Chief. My love for the stock markets goes back to when I was a kid. Who else remembers combing through the stock quotes at the back of the business section of your local paper?
I joined Seeking Alpha in 2006 and launched Wall Street Breakfast and Market Currents, our top-of-class short-form breaking news for investors. In 2010 I became editor-in-chief and in 2015 I became CEO.
I live in Jerusalem with my wife and a bunch of exceptional kids. Most days, you'll find me making the commute from Jerusalem to Raanana. Occasionally I get to work from my home-office, from where I keep an eye on the beautiful Judean Hills.
To contact me, send me a direct message, or email me at email@example.com.
Investing for about 25 years and enjoy analyzing companies, especially special situations. I live in the US, have a PhD in the biological sciences, with about 20 years experience In clinical development and commercialiation/marketing of Therapeutic biologics, small molecules, and medical devices.
As I have grown older, my philosophy has evolved from one of short-term trading, to finding stocks that can be held longer-term, preferably forever. I enjoy researching biotech stocks, but seldom invest here due to the volatility and risks. I rely on my own fundamental analysis but will also consider chart patterns when deciding opportunities to buy or sell. I always do my best to figure in investor & analyst psychology, and use basic financials to reassure me of my analysis (including mistakes) when volatility gets extreme. Do not consider myself to be an expert on technical analysis and as a scientist with training in statistics, am skeptical of that the historical movements of a stock can be used to reliably forecast buy/sell signals (if charting were that reliable as a predictive indicator, everyone would be using this to their advantage).
In addition to looking at company's financials, I like to consider companies that are positioned to capitalize on changing demographics (growing per capita income in developing countries, aging of America, obesity epidemic, etc.), and strongly prefer companies with a wide economic moat. I frequently sell covered calls to mitigate and take adtvantage of market volatility. When I find a high conviction company that I want to own, not infrequently I will sell naked puts to reduce my cost basis and generate some cash flow.